Market Closed -
Bombay S.E.
06:00:59 2024-07-04 am EDT
|
5-day change
|
1st Jan Change
|
61.34
INR
|
+0.81%
|
|
+2.13%
|
-7.87%
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
2,484
|
1,297
|
897.1
|
2,136
|
3,073
|
2,872
|
Enterprise Value (EV)
1 |
2,277
|
1,367
|
1,073
|
2,318
|
3,109
|
2,761
|
P/E ratio
|
-18.2
x
|
-41.5
x
|
8.32
x
|
-175
x
|
13.9
x
|
24.8
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
22.3
x
|
9.95
x
|
3.46
x
|
11
x
|
9.33
x
|
7.36
x
|
EV / Revenue
|
20.4
x
|
10.5
x
|
4.14
x
|
12
x
|
9.44
x
|
7.08
x
|
EV / EBITDA
|
-29.1
x
|
-42
x
|
11.9
x
|
36.3
x
|
17.4
x
|
12.9
x
|
EV / FCF
|
-7.97
x
|
-4.86
x
|
-4.92
x
|
-148
x
|
26.6
x
|
26
x
|
FCF Yield
|
-12.5%
|
-20.6%
|
-20.3%
|
-0.68%
|
3.75%
|
3.84%
|
Price to Book
|
5.91
x
|
3.33
x
|
1.81
x
|
4.41
x
|
4.35
x
|
3.49
x
|
Nbr of stocks (in thousands)
|
61,031
|
61,031
|
61,031
|
61,031
|
61,031
|
61,031
|
Reference price
2 |
40.70
|
21.25
|
14.70
|
35.00
|
50.35
|
47.06
|
Announcement Date
|
9/6/18
|
8/27/19
|
9/2/20
|
9/2/21
|
8/30/22
|
9/5/23
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
111.4
|
130.3
|
259.4
|
193.7
|
329.5
|
390.1
|
EBITDA
1 |
-78.16
|
-32.59
|
89.8
|
63.8
|
179.2
|
213.6
|
EBIT
1 |
-117.2
|
-74.61
|
41.3
|
-0.76
|
109.4
|
141.9
|
Operating Margin
|
-105.16%
|
-57.27%
|
15.92%
|
-0.39%
|
33.21%
|
36.37%
|
Earnings before Tax (EBT)
1 |
-118.5
|
-31.27
|
107.8
|
-12.15
|
99.01
|
145
|
Net income
1 |
-118.5
|
-31.27
|
107.8
|
-12.15
|
221.8
|
115.9
|
Net margin
|
-106.34%
|
-24%
|
41.55%
|
-6.27%
|
67.31%
|
29.7%
|
EPS
2 |
-2.240
|
-0.5124
|
1.766
|
-0.2000
|
3.630
|
1.898
|
Free Cash Flow
1 |
-285.6
|
-281.4
|
-218.3
|
-15.66
|
116.7
|
106.1
|
FCF margin
|
-256.25%
|
-215.95%
|
-84.16%
|
-8.08%
|
35.43%
|
27.19%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
65.15%
|
49.66%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
52.64%
|
91.56%
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
9/6/18
|
8/27/19
|
9/2/20
|
9/2/21
|
8/30/22
|
9/5/23
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
70.4
|
176
|
182
|
35.9
|
-
|
Net Cash position
1 |
207
|
-
|
-
|
-
|
-
|
111
|
Leverage (Debt/EBITDA)
|
-
|
-2.161
x
|
1.957
x
|
2.852
x
|
0.2001
x
|
-
|
Free Cash Flow
1 |
-286
|
-281
|
-218
|
-15.7
|
117
|
106
|
ROE (net income / shareholders' equity)
|
99.2%
|
-7.73%
|
24.3%
|
-2.48%
|
37.3%
|
15.2%
|
ROA (Net income/ Total Assets)
|
-11.1%
|
-5.61%
|
3.03%
|
-0.06%
|
7.6%
|
9.1%
|
Assets
1 |
1,072
|
557.7
|
3,552
|
21,933
|
2,917
|
1,274
|
Book Value Per Share
2 |
6.880
|
6.370
|
8.130
|
7.930
|
11.60
|
13.50
|
Cash Flow per Share
2 |
4.650
|
2.160
|
0.1800
|
0.4000
|
0.4000
|
1.830
|
Capex
1 |
38.2
|
180
|
217
|
49.1
|
19.4
|
62.3
|
Capex / Sales
|
34.32%
|
138.41%
|
83.84%
|
25.35%
|
5.88%
|
15.97%
|
Announcement Date
|
9/6/18
|
8/27/19
|
9/2/20
|
9/2/21
|
8/30/22
|
9/5/23
|
|
1st Jan change
|
Capi.
|
---|
| -7.87% | 44.48M | | +54.07% | 809B | | +38.95% | 621B | | -7.05% | 351B | | +15.44% | 319B | | +5.72% | 289B | | +14.21% | 238B | | -0.45% | 221B | | +14.58% | 218B | | +7.42% | 166B |
Other Pharmaceuticals
|